Woodline Partners LP Biogen Inc. Transaction History

Woodline Partners LP

$9.97 Billion
Q2 2024

A detailed history of Woodline Partners LP transactions in Biogen Inc. stock. As of the latest transaction made, Woodline Partners LP holds 80,600 shares of BIIB stock, worth $14 Million. This represents 0.19% of its overall portfolio holdings.

Number of Shares

80,600

Previous 80,600 -0.0%

Holding current value

$14 Million

Previous $17.4 Million 7.51%

% of portfolio

0.19%

Previous 0.17%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$222.59 - $267.94 $17.9 Million - $21.6 Million	80,600 New	80,600 $20.9 Million
Q2 2023 Aug 14, 2023	SELL	$275.25 - $318.06 $38.8 Million - $44.8 Million	-140,865 Reduced 98.45%	2,213 $630,000
Q1 2023 May 15, 2023	BUY	$256.56 - $292.34 $27.6 Million - $31.4 Million	107,569 Added 302.93%	143,078 $39.8 Million
Q4 2022 Feb 14, 2023	SELL	$252.44 - $306.72 $9.71 Million - $11.8 Million	-38,445 Reduced 51.99%	35,509 $9.83 Million
Q3 2022 Nov 14, 2022	BUY	$194.69 - $268.46 $7.11 Million - $9.81 Million	36,542 Added 97.67%	73,954 $19.7 Million
Q2 2022 Aug 15, 2022	SELL	$187.54 - $223.02 $3.12 Million - $3.71 Million	-16,655 Reduced 30.8%	37,412 $7.63 Million
Q1 2022 May 16, 2022	BUY	$193.77 - $244.14 $3.16 Million - $3.98 Million	16,286 Added 43.11%	54,067 $11.4 Million
Q4 2021 Feb 14, 2022	SELL	$223.92 - $287.77 $3.28 Million - $4.21 Million	-14,637 Reduced 27.92%	37,781 $9.06 Million
Q3 2021 Nov 15, 2021	SELL	$282.99 - $369.05 $5.95 Million - $7.76 Million	-21,039 Reduced 28.64%	52,418 $14.8 Million
Q2 2021 Aug 16, 2021	BUY	$259.0 - $414.71 $14.5 Million - $23.2 Million	55,981 Added 320.33%	73,457 $25.4 Million
Q1 2021 May 17, 2021	BUY	$242.95 - $284.63 $4.25 Million - $4.97 Million	17,476 New	17,476 $4.89 Million

Others Institutions Holding BIIB

# of Institutions

1,018

Shares Held

128M

Call Options Held

1.22M

Put Options Held

1.4M

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Woodline Partners LP with notifications on news.

Account

Woodline Partners LP Biogen Inc. Transaction History